{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:48:08Z","timestamp":1782712088694,"version":"3.54.5"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Generic pramipexole is widely prescribed for Parkinson\u2019s disease (PD), yet clinical equivalence to the brand-name formulation remains debated. We aimed to compare generic and brand-name pramipexole dihydrochloride tablets in real world.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a multicenter retrospective propensity score-matched cohort study. Prescription data of outpatients using either generic or brand-name pramipexole dihydrochloride tablets for PD or Parkinson\u2019s syndrome were extracted at five research hospitals from July 1, 2018, to June 30, 2023. Effectiveness was assessed by changes in levodopa equivalent dose (LED) over time, while safety was evaluated by adverse events (AEs) from enrollment to follow-up completion. Medication costs were also compared between the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 1,063 patients in the brand-name drug group and 1,287 in the generic drug group were included. A total of 161 AEs occurred in the generic drug group and 182 in the brand-name drug group. There was no significant difference in AE occurrence between the two groups (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.898). And no significant difference was found in the change degree of LED level between generic drug and brand-name drug group over time (\n                      <jats:italic>H<\/jats:italic>\n                      = 1.514,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.824). The daily cost of pramipexole and antiparkinsonian drug, as well as the average prescription cost over 1 year of follow-up in the generic drug group were significantly lower than those in the brand-name drug group (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>With comparable efficacy and safety, our results indicate the generic pramipexole should be considered a valuable alternative to the brand-name drug. Future prospective research is needed to confirm these findings in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnagi.2026.1873459","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:40:58Z","timestamp":1782711658000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Generic vs. brand-name pramipexole: effectiveness, safety, and cost comparison in a multicenter retrospective cohort study"],"prefix":"10.3389","volume":"18","author":[{"given":"Ke","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Xuanwu Hospital of Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxuan","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xuanwu Hospital of Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhizhou","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xuanwu Hospital of Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xuanwu Hospital of Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Hospital of Hebei Medical University, Hebei","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Soochow University, Jiangsu","place":["Suzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Inner Mongolia Autonomous Region People\u2019s Hospital, Inner Mongolia","place":["Hohhot, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changzhi","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xuanwu Hospital of Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhe","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xuanwu Hospital of Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1248\/yakushi.19-00029","article-title":"Comparison of the pharmaceutical characteristics of brand-name and generic pramipexole extended-release tablets and their PTP usability.","volume":"139","author":"Akiyama","year":"2019","journal-title":"Yakugaku Zasshi"},{"key":"B2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson disease: A review.","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(23)01419-8","article-title":"The epidemiology of Parkinson\u2019s disease.","volume":"403","author":"Ben-Shlomo","year":"2024","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/14740338.2024.2305709","article-title":"Generic pharmaceuticals, regulatory aspects, bioequivalence investigation, and perception.","volume":"23","author":"Bhushan","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B5","first-page":"S168","article-title":"The economic and quality of life burden associated with Parkinson\u2019s disease: A focus on symptoms.","volume":"18","author":"Boland","year":"2012","journal-title":"Am. J. Manag. Care"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e2214153","DOI":"10.1001\/jamanetworkopen.2022.14153","article-title":"Association of inappropriate outpatient pediatric antibiotic prescriptions with adverse drug events and health care expenditures.","volume":"5","author":"Butler","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s40262-020-00912-z","article-title":"Converging generic drug product development: Bioequivalence design and reference product selection.","volume":"59","author":"Charoo","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"973310","DOI":"10.3389\/fnagi.2022.973310","article-title":"The long-term trend of Parkinson\u2019s disease incidence and mortality in China and a Bayesian projection from 2020 to 2030.","volume":"14","author":"Chen","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/WNF.0000000000000400","article-title":"The efficacy and safety of piribedil relative to pramipexole for the treatment of early Parkinson disease: A systematic literature review and network meta-analysis.","volume":"43","author":"Chen","year":"2020","journal-title":"Clin. Neuropharmacol."},{"key":"B10","volume-title":"Consumer Price Index (CPI) for Medicines and Medical Instruments for Urban Residents.","year":"2023"},{"key":"B11","volume-title":"National Annual Statistical Bulletin.","year":"2024"},{"key":"B12","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3760\/cma.j.cn113694-20200331-00233","article-title":"Chinese guidelines for the treatment of Parkinson\u2019s disease (fourth edition).","volume":"53","year":"2020","journal-title":"Chin. J. Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JPD-181474","article-title":"The emerging evidence of the Parkinson pandemic.","volume":"8","author":"Dorsey","year":"2018","journal-title":"J. Parkinsons Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3390\/jpm12050813","article-title":"Personalized care in late-stage Parkinson\u2019s disease: Challenges and opportunities.","volume":"12","author":"Fabbri","year":"2022","journal-title":"J. Pers. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.18549\/PharmPract.2018.04.1220","article-title":"The effect of pramipexole extended release on the levodopa equivalent daily dose in Lebanese Parkinson diseased patients.","volume":"16","author":"Faddoul","year":"2018","journal-title":"Pharm. Pract."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson\u2019s disease.","volume":"33","author":"Fox","year":"2018","journal-title":"Mov. Disord."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1007\/s40265-014-0322-5","article-title":"Pramipexole extended-release: A review of its use in patients with Parkinson\u2019s disease.","volume":"74","author":"Frampton","year":"2014","journal-title":"Drugs"},{"key":"B18","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/s1474-4422(18)30295-3","article-title":"Global, regional, and national burden of Parkinson\u2019s disease, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016.","volume":"17","year":"2018","journal-title":"Lancet Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.parkreldis.2011.02.005","article-title":"Generic versus branded pharmacotherapy in Parkinson\u2019s disease: Does it matter? A review.","volume":"17","author":"Go","year":"2011","journal-title":"Parkinsonism Relat. Disord."},{"key":"B20","doi-asserted-by":"publisher","first-page":"E989","DOI":"10.1503\/cmaj.181504","article-title":"Canadian guideline for Parkinson disease.","volume":"191","author":"Grimes","year":"2019","journal-title":"CMAJ"},{"key":"B21","doi-asserted-by":"publisher","first-page":"277","DOI":"10.5694\/mja2.50224","article-title":"Updates and advances in the treatment of Parkinson disease.","volume":"211","author":"Hayes","year":"2019","journal-title":"Med. J. Aust."},{"key":"B22","doi-asserted-by":"publisher","first-page":"102691","DOI":"10.1016\/j.ajp.2021.102691","article-title":"The role of pramipexole in the treatment of patients with depression and Parkinson\u2019s disease: A meta-analysis of randomized controlled trials.","volume":"61","author":"Jiang","year":"2021","journal-title":"Asian J. Psychiatr."},{"key":"B23","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40520-019-01232-4","article-title":"Comparison of selegiline and levodopa combination therapy versus levodopa monotherapy in the treatment of Parkinson\u2019s disease: A meta-analysis.","volume":"32","author":"Jiang","year":"2020","journal-title":"Aging Clin. Exp. Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e0338409","DOI":"10.1371\/journal.pone.0338409","article-title":"Impact of Chinese national centralized volume-based drug procurement policy on health costs and utilization: An interrupted time series analysis using panel data (2009-2022).","volume":"20","author":"Jiang","year":"2025","journal-title":"PLoS One"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/mds.29410","article-title":"Levodopa dose equivalency in Parkinson\u2019s disease: Updated systematic review and proposals.","volume":"38","author":"Jost","year":"2023","journal-title":"Mov. Disord."},{"key":"B26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40035-019-0162-z","article-title":"Parkinson\u2019s disease in China: A forty-year growing track of bedside work.","volume":"8","author":"Li","year":"2019","journal-title":"Transl. Neurodegener."},{"key":"B27","doi-asserted-by":"publisher","first-page":"5160","DOI":"10.3969\/j.issn.1005-9202.2018.21.017","article-title":"Blood glucose level, motor function and levodopa equivalent dose in patients with Parkinson\u2019s disease and type 2 diabetes mellitus.","volume":"38","author":"Li","year":"2018","journal-title":"Chin. J. Gerontol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e14531","DOI":"10.1111\/cns.14531","article-title":"Comparison of the effectiveness, safety, and costs of anti-Parkinson drugs: A multiple-center retrospective study.","volume":"30","author":"Li","year":"2024","journal-title":"CNS Neurosci. Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1662346","DOI":"10.3389\/fpubh.2025.1662346","article-title":"Effect of the national reimbursement drug list negotiation policy on utilization of negotiated anticancer drugs in Chinese public hospital: A quasi-natural experiment.","volume":"13","author":"Liu","year":"2025","journal-title":"Front. Public Health"},{"key":"B30","unstructured":"Parkinson\u2019s Disease in Adults.\n          \n          2017"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1001\/jama.2023.15503","article-title":"Treatment failure and adverse events after amoxicillin-clavulanate vs amoxicillin for pediatric acute sinusitis.","volume":"330","author":"Savage","year":"2023","journal-title":"JAMA"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1227102","DOI":"10.3389\/fpubh.2023.1227102","article-title":"Impact of China\u2019s National Centralized Drug Procurement Policy on pharmaceutical enterprises\u2019 financial performance: A quasi-natural experimental study.","volume":"11","author":"Sun","year":"2023","journal-title":"Front. Public Health"},{"key":"B33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","article-title":"Challenges in the diagnosis of Parkinson\u2019s disease.","volume":"20","author":"Tolosa","year":"2021","journal-title":"Lancet Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e086810","DOI":"10.1136\/bmj-2025-086810","article-title":"Concordance between target trial emulation and randomised controlled trials: Systematic review and meta-analysis.","volume":"393","author":"Wang","year":"2026","journal-title":"BMJ"},{"key":"B35","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12939-023-02006-1","article-title":"The impact of the national volume-based procurement policy on the use of policy-related drugs in Nanjing: An interrupted time-series analysis.","volume":"22","author":"Wang","year":"2023","journal-title":"Int. J. Equity Health"},{"key":"B36","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s11096-020-01023-2","article-title":"Effects of generic exchange of solid oral dosage forms in neurological disorders: A systematic review.","volume":"42","author":"Weitzel","year":"2020","journal-title":"Int. J. Clin. Pharm."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.2147\/DDDT.S421449","article-title":"Comparative pharmacokinetics and bioequivalence evaluation of two formulations of pramipexole dihydrochloride extended-release tablets in healthy Chinese subjects under fasted and fed states: A randomized, open-label, single-dose, two-period crossover clinical trial.","volume":"17","author":"Yang","year":"2023","journal-title":"Drug Des. Devel. Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1002\/hpm.3429","article-title":"The impact of National Centralised Drug Procurement policy on the use of policy-related original and generic drugs in China.","volume":"37","author":"Yang","year":"2022","journal-title":"Int. J. Health Plann. Manage."},{"key":"B39","doi-asserted-by":"publisher","first-page":"330","DOI":"10.21037\/atm-22-1014","article-title":"Evaluating the direct medical cost, drug utilization and expenditure for managing Parkinson\u2019s disease: A costing study at a medical center in China.","volume":"10","author":"Yi","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/CM9.0000000000001360","article-title":"Evaluation of blood pressure lowering effect by generic and brand-name antihypertensive drugs treatment: A multicenter prospective study in China.","volume":"134","author":"Zhang","year":"2021","journal-title":"Chin. Med. J."},{"key":"B41","doi-asserted-by":"publisher","first-page":"7724","DOI":"10.34172\/ijhpm.2023.7724","article-title":"Impact of China\u2019s national volume-based procurement on drug procurement price, volume, and expenditure: An interrupted time series analysis in Tianjin.","volume":"12","author":"Zhao","year":"2023","journal-title":"Int. J. Health Policy Manag."},{"key":"B42","doi-asserted-by":"publisher","first-page":"7749","DOI":"10.3390\/ijerph18157749","article-title":"Physicians\u2019 knowledge, attitude and practice of generic substitution in China: A cross-sectional online survey.","volume":"18","author":"Zhao","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1873459\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:41:02Z","timestamp":1782711662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1873459\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":42,"alternative-id":["10.3389\/fnagi.2026.1873459"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2026.1873459","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"article-number":"1873459"}}